



## Summary of decisions & actions arising from the EDCTP Association Board meeting on 10 October 2017, 11:00-12:30 CEST

Participants:			
Mark Palmer (MP) - Chairperson	Yazdan Yazdanpanah (YY) – <i>joined 10 minutes late</i>		
Eusébio Macete (EM) – <i>joined 30 minutes late</i>	Detlef Böcking (DB)		
Cate Hankins (CH) - observer	Michael Makanga (MM)		
Gianpietro van de Goor (EC) – observer – <i>joined 20 minutes late</i>	Denise O'Conner (EC) – observer		
Lara Pandya (LP) – observer (notes)			
Apologies:			
Francine Ntoumi (FN)	Line Matthiessen (EC) - observer		
Summary of Decisions and Action Points			
Agenda item & subject	Decisions and actions	Action by	Due date
1.1 Notes of the Board teleconference held on 12 September 2017	<u>Decision:</u> The Board approved the notes of the Board teleconference of 12 September 2017.		
2.1: Draft agenda for the GA of 9-10 November 2017	<u>Decisions:</u> <ul style="list-style-type: none"> <li>The Board approved the draft agenda for the GA of 9-10 November 2017.</li> <li>The Board approved the format and level of content of the GA agenda and decisions &amp; actions summary for publication on the EDCTP website.</li> </ul>		
3.1 Change of Coordinator for ethics application CSA2016ERC-1414	<u>Decision:</u> The Board approved the change of coordinator for ethics application CSA2016ERC-1414.		
3.2 Stimulating the development and strengthening of the national health research systems (NHRS) of EDCTP African Partner States	<u>Decision:</u> The Board approved employing approach 1 using consultants, provided the consultancy firm selected would be required to work closely with both WHO AFRO and the African PS representatives throughout the duration of the activity.		

DMS # 103561

Meeting of the EDCTP Association Board

11:00-12:30 CEST

Tuesday, 10 October 2017



**E D C T P**

European & Developing Countries  
Clinical Trials Partnership

## Summary of decisions & actions arising from the EDCTP Association Board meeting on 10 October 2017, 11:00-12:30 CEST

3.4.2 Secondment of Product Development expert from Novartis	<u>Decision:</u> The Board approved that the SEC could proceed with finalising the arrangements for a secondment of the product development expert proposed by Novartis.		
--	---	--	--